3
Announcements
Trials
Browse
Landscape
Status
Completed
2
Active not recruiting
2
Recruiting
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Observational
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Breast Neoplasms
660
Carcinoma, Non-Small-Cell Lung
454
Prostatic Neoplasms
384
Neoplasms
376
Lung Neoplasms
261
Multiple Myeloma
246
Colorectal Neoplasms
231
Neoplasm Metastasis
214
Melanoma
202
Leukemia, Myeloid, Acute
165
Ovarian Neoplasms
163
Pancreatic Neoplasms
155
Carcinoma, Renal Cell
141
Squamous Cell Carcinoma of Head and Neck
137
Lymphoma
134
Brain Neoplasms
132
Leukemia, Lymphocytic, Chronic, B-Cell
126
Glioblastoma
126
Recurrence
123
Lymphoma, Non-Hodgkin
123
Carcinoma, Hepatocellular
117
Head and Neck Neoplasms
114
Urinary Bladder Neoplasms
111
Triple Negative Breast Neoplasms
107
Stomach Neoplasms
106
Precursor Cell Lymphoblastic Leukemia-Lymphoma
104
Uterine Cervical Neoplasms
100
Hematologic Neoplasms
99
Lymphoma, Follicular
95
Sarcoma
93
Interventions
enzalutamide
1
apalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Active not recruiting
×
Metastatic Hormone-sensitive Prostate Cancer
×
1 year
×
Clear all
NCT05901649
2026-06-05
ArtemisPRO
Janssen-Cilag Ltd.
Active not recruiting
504 enrolled
NCT06874114
2026-04-13
RE-ENGAGE
Bayer
Active not recruiting
700 enrolled